Cochrane Answer: Can hormone replacement supplements be used in endometrial cancer patients after comprehensive treatment?

Why did the old saying come back? Endometrial cancer is the sixth most common malignant tumor among women among women between the world and is common after menoanth (75%).
319,000 new cases worldwide in 2012.
endometrial cancer is often considered a potential "curable cancer" and about 75% of cases are diagnosed before the lesions reach outside the uterus.FIGO (International Federation of Obstetrics and Gynecologists) Phase I.
five-year survival rate for all phases is about 86 per cent, the tumour is confined to the uterus, and the five-year survival rate may increase to 97 per cent.
most diagnosed endometrial cancers are early-stage diseases, with a good prognosis after hysterectomy and fallopian tube-ovary removal (ovarian excision).
, however, depending on the age at which the diagnosis is made, women may have early post-menopanic physical and psychological changes, available or as a result of ovarian excision.
lack of estrogen can lead to long-term adverse reactions such as hot water, night sweats, atrophy of the reproductive tract and osteoporosis and cardiovascular disease.
these changes can be temporarily controlled by using estrogen in the form of hormone replacement therapy (HRT).
, however, there is a theoretical risk that HRT will promote the growth of residual tumor cells and increase cancer recurrence.
, this is a potential survival defect for women with potentially treatable endometrial cancer.
women with pre-menopaneous endometrial cancer, ovarian loss leads to early menoanphage, which can have an adverse effect on overall survival rates.
needs to understand the risks and benefits of taking HRT so that endometrial cancer patients can make informed decisions that weigh the pros and cons of using HRT to meet their individual physiological needs.
the latest system review from Cochrane Database of System Reviews, which is now shared. DOI: 10.1002/14651858.CD008830.pub3.) What is the meaning? Assess the risks and benefits of HRT (estrogen alone or estrogen-combined) in women who have been treated for endometrial cancer in the past.
can I verify? Search for Cochrane controlled trial registration (CENTRAL 2017, No. 5), MEDLINE (April 1946, week 4, 2017) and Embase (1980-2017, week 18).
also retrieve reference lists for clinical trial registrations, scientific conference summaries, and commentary articles.
includes randomized controlled trials (RCTs) in all languages, which provide the effectiveness of symptom relief and the safety of using HRT to treat women with endometrial cancer, which is considered to do not increase the risk of recurrence of endometrial cancer compared to women who do not use HRT.
the result? Identify 2,190 different records and evaluate the full text of seven studies, including one involving 1,236 participants.
the study reported a recurrence of 2.3 percent of tumors in the estrogen group, compared with 1.9 percent in placebo women with a 1.17 percent risk ratio (RR), a 95 percent confidence interval (CI) of 0.54 to 2.50, and very low determinative evidence.
the study reported that 1 female in the HRT group (0.16%) and 3 women in the placebo group (0.49%) had breast cancer (new tumors) during follow-up (RR 0.80, 95% CI 0.32 to 2.01; 1,236 participants, 1 study; very low determinative evidence.
the study did not report symptom relief, total survival, or progression-free survival compared to placebo.
However, the proportion of people who did not progress at the end of follow-up at the end of 36 months (94.3 per cent in the HRT group and 95.6 per cent in the placebo group) and 95.8 per cent in the placebo group and 96.9 per cent in the placebo group were reported.
the study did not report a recurrence time and lacked evidence due to an early end.
published as a result of the Women's Health Initiative (WHI) study, which showed at the time that the risks of exogenetic hormone therapy outweighed the benefits and had an impact on research recruitment.
did not report an assessment of efficacy.
's the conclusion? Currently, there is not enough high-quality evidence to inform women to consider HRT after treatment for endometrial cancer.
if HRT is used after early endometrial cancer surgery, the available evidence (including single RCT and non-random evidence) does not indicate significant harm.
there is no information on the use of HRT in highly staged endometrial cancer (FIGO Phase II and above).
suggests that HRT should consider individualization after endometrial cancer treatment, taking into account women's symptoms and preferences, as well as uncertainty about evidence of non-use of HRT.
YuanHang Zhang Shi former source: Zhang Shi former public number copyright notice: All the text, pictures and audio and video materials marked "Source: Mays Medicine" or "Source: MedSci Original" are owned by Meis Medical, without authorization, no media, website or individual may be reproduced, authorized to reproduce with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here